Details for New Drug Application (NDA): 202788
✉ Email this page to a colleague
NDA 202788 describes SUBSYS, which is a drug marketed by Btcp Pharma and is included in one NDA. There are ten patents protecting this drug and two Paragraph IV challenges. Additional details are available on the SUBSYS profile page.
The generic ingredient in SUBSYS is fentanyl. There are thirty-one drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the fentanyl profile page.
The generic ingredient in SUBSYS is fentanyl. There are thirty-one drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the fentanyl profile page.
Summary for 202788
| Tradename: | SUBSYS |
| Applicant: | Btcp Pharma |
| Ingredient: | fentanyl |
| Patents: | 10 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 202788
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SPRAY;SUBLINGUAL | Strength | 0.1MG | ||||
| Approval Date: | Jan 4, 2012 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Try a Trial | Patent Expiration: | Jan 25, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Try a Trial | Patent Expiration: | Jan 25, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Try a Trial | Patent Expiration: | Apr 27, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
